Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TG Therapeutics Inc (NASDAQ:TGTX)

11.77
Delayed Data
As of Sep 01
 -0.51 / -4.15%
Today’s Change
8.38
Today|||52-Week Range
20.00
-25.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$645.3M

Company Description

TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. The TG-1101 is a third generation, type I chimeric IgG1 monoclonal antibody with a glycoengineered Fc region designed specifically to induce higher ADCC activity in comparison to rituximab, which has been demonstrated in pre-clinical models. The TGR-1202, is an orally available PI3K delta inhibitor. TG Therapeutics was founded by Michael S. Weiss on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
3 Columbus Circle
New York New York 10019
P:(212) 554-4484
Investor Relations:
(212) 554-4351

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Michael S. WeissExecutive Chairman, President & CEO
Sean A. PowerCFO, Secretary, Treasurer & CAO
Robert NiecestroExecutive Vice President-Clinical & Regulatory
Hari MiskinHead-Business Development
Jenna A. BoscoDirector-Investor Relations